Q3 FY25 Quarterly Activities Report & Appendix 4C

Key points

• Continued strong sales momentum for MetaXplore testing in Australia and UK
• Landmark IBD study results and partnership with major gastroenterology group in Australia
• Transition to focus on core diagnostic products and partnering for therapeutics

Full summary

Microba Life Sciences reported a strong Q3 FY25, with continued growth in testing sales in Australia and the UK. In Australia, MetaXplore test sales were up 201% year-over-year, driven by an increase in ordering clinicians while maintaining average order per clinician. MetaPanel adoption is also building, with sales up 1,827% year-over-year, following landmark IBD study results and a strategic partnership with the Colonoscopy Clinic, a major private gastroenterology group, to integrate Microba's testing into clinical protocols. In the UK, MetaXplore test sales demonstrated strong month-on-month growth, now representing 39% of total GI tests sold. Microba is accelerating to full market access in the UK by the end of June 2025. The company's therapeutics business has transitioned to a partnering-focused phase, with multiple pathways being executed to bring assets to patients and generate returns for shareholders. Financially, Microba provided FY25 revenue guidance of $15.25m to $16.25m, up 26-34% year-over-year, with Q3 cash receipts of $4.23m, up 5% versus the prior corresponding period.

Guidance

FY25 revenue expected to be in the range of $15.25m - $16.25m, up 26% - 34% versus the prior corresponding period.

Outlook

Microba continues to see strong growth and clinical adoption of its tests in Australia and the UK. The company is focused on partnering to advance its therapeutics assets and bring them to patients, with multiple commercial streams to deliver a return on investment for shareholders.